Trial Outcomes & Findings for HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function (NCT NCT03902366)

NCT ID: NCT03902366

Last Updated: 2025-03-27

Results Overview

The Memory Module is a marker of learning, recall, and recognition memory. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Memory Module subtests include: List Learning, Shape Learning, Story Learning, and Daily Living Memory. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in memory performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of memory performance over time.

Recruitment status

COMPLETED

Target enrollment

63 participants

Primary outcome timeframe

Baseline and 6 months

Results posted on

2025-03-27

Participant Flow

Of 119 assessed for eligibility, 63 met inclusion criteria (38 AUD-/HCV-, 20 AUD+/HCV-, 5 HCVc) and were enrolled in the study. 17 participants were excluded after enrollment. Due to low recruitment numbers and no significant differences between the HCV groups, individuals with a history of HCV were assigned to one group (HCVc).

Participant milestones

Participant milestones
Measure
Control (AUD-/HCV-)
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+/HCV-)
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
-Adults with cleared HCV (i.e. no longer test positive for HCV) after receiving treatment (HCVc) Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Baseline
STARTED
27
14
5
Baseline
COMPLETED
27
14
5
Baseline
NOT COMPLETED
0
0
0
Follow-up
STARTED
27
14
5
Follow-up
COMPLETED
27
14
5
Follow-up
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Total
n=46 Participants
Total of all reporting groups
Age, Continuous
53.70 years
STANDARD_DEVIATION 14.87 • n=39 Participants
59.71 years
STANDARD_DEVIATION 13.84 • n=41 Participants
63.40 years
STANDARD_DEVIATION 5.37 • n=35 Participants
56.59 years
STANDARD_DEVIATION 14.10 • n=31 Participants
Sex: Female, Male
Female
9 Participants
n=39 Participants
4 Participants
n=41 Participants
1 Participants
n=35 Participants
14 Participants
n=31 Participants
Sex: Female, Male
Male
18 Participants
n=39 Participants
10 Participants
n=41 Participants
4 Participants
n=35 Participants
32 Participants
n=31 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
3 Participants
n=31 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
n=39 Participants
14 Participants
n=41 Participants
5 Participants
n=35 Participants
43 Participants
n=31 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants
n=39 Participants
0 Participants
n=41 Participants
1 Participants
n=35 Participants
3 Participants
n=31 Participants
Race (NIH/OMB)
Asian
1 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
1 Participants
n=31 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
Race (NIH/OMB)
Black or African American
5 Participants
n=39 Participants
2 Participants
n=41 Participants
1 Participants
n=35 Participants
8 Participants
n=31 Participants
Race (NIH/OMB)
White
16 Participants
n=39 Participants
12 Participants
n=41 Participants
3 Participants
n=35 Participants
31 Participants
n=31 Participants
Race (NIH/OMB)
More than one race
3 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
3 Participants
n=31 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
Region of Enrollment
United States
27 Participants
n=39 Participants
14 Participants
n=41 Participants
5 Participants
n=35 Participants
46 Participants
n=31 Participants

PRIMARY outcome

Timeframe: Baseline and 6 months

The Attention Module is a marker of attentional capacity, working memory, and processing speed. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Attention Module subtests include: Dots, Numbers and Letters, Driving Scenes, Digits Forward, and Digits Backward. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in attention performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of attention performance over time.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores
10.99 Units on a scale
Standard Deviation 3.37
0.31 Units on a scale
Standard Deviation 1.18
6.35 Units on a scale
Standard Deviation 5.92

PRIMARY outcome

Timeframe: Baseline and 6 months

The Memory Module is a marker of learning, recall, and recognition memory. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Memory Module subtests include: List Learning, Shape Learning, Story Learning, and Daily Living Memory. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in memory performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of memory performance over time.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores
9.07 Units on a scale
Standard Deviation 1.12
1.95 Units on a scale
Standard Deviation 1.52
3.50 Units on a scale
Standard Deviation 0.71

PRIMARY outcome

Timeframe: Baseline and 6 months

The Executive Functions Module of the NAB is a marker of executive function, including problem-solving and mental flexibility. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Executive Function Module subtests include: Mazes, Judgement, Categories, and Word Generation. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in executive function performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of executive functioning performance over time.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores
10.65 Units on a scale
Standard Deviation 0.25
5.46 Units on a scale
Standard Deviation 1.01
18.00 Units on a scale
Standard Deviation 14.14

PRIMARY outcome

Timeframe: Baseline and 6 months

This outcome measure evaluates the change in the number of days of alcohol use from baseline to a 6-month follow-up, using the 30-Day Timeline Followback (TLFB) method. The TLFB is a structured, retrospective interview technique that allows participants to accurately recall their alcohol consumption patterns over the previous 30 days. For this outcome, the number of days on which alcohol was consumed will be assessed at baseline (the start of the study) and again at the 6-month follow-up assessment. A positive change would indicate an increase in the number of days of alcohol use, while a negative change would indicate a reduction in the number of days of alcohol use over the 6-month period.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB)
3.78 change in the number of days of alcohol
Standard Deviation 9.69
44.00 change in the number of days of alcohol
Standard Deviation 81.85
-6.25 change in the number of days of alcohol
Standard Deviation 12.5

PRIMARY outcome

Timeframe: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, one control participant and one participant with cleared HCV (HCVc) were not included in the analysis because task data from at least one timepoint was not collected.

The BART is a computerized measure of risk-taking behavior that concurrently measures several domains (i.e., risky decision-making, reward/negative outcome processing) during fMRI scanning. The ratio of balloon pumps made to maximum pumps allowed is a measure of risk-taking behavior. A ratio of 1 indicates that a participant inflated the balloon to its maximum allowed pumps, while a ratio closer to 0 suggests that the participant was much more conservative in their approach. Change was calculated as the value at 6 months minus the value at baseline and ranges from -1 to 1. A positive change indicates an increase in risk-taking behavior and a negative change indicates a decrease in risk-taking behavior over time.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=14 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=9 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=3 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART)
-0.018 ratio
Standard Deviation 0.093
-0.005 ratio
Standard Deviation 0.079
-0.014 ratio
Standard Deviation 0.164

PRIMARY outcome

Timeframe: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, two participants (1 HCVc, 1 AUD) were excluded from the study for having incomplete task data.

The MID is a validated task to examine anticipatory brain responses to reward during fMRI scanning. This outcome measure evaluates the change in reaction time (RT) of participants in response to monetary reward cues during the MID. Reaction time is defined as the duration (in milliseconds) from the presentation of the cue to the participant's response (e.g., button press). The MID involves various reward conditions, including different monetary values and probabilities, allowing for an evaluation of participants' anticipatory responses to potential rewards. A positive difference indicates an increase in RT at 6-months compared to baseline, suggesting potential decreases in motivation, cognitive load, or changes in reward sensitivity. Conversely, a negative difference indicates a decrease in reaction time, which may reflect improved motivation, enhanced cognitive processing speed, or increased responsiveness to monetary incentives over time.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=15 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=8 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=3 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task
-0.39 milliseconds
Standard Deviation 22.83
12.77 milliseconds
Standard Deviation 19.78
3.63 milliseconds
Standard Deviation 14.17

PRIMARY outcome

Timeframe: Baseline and 6 months

The Fatigue Severity Scale (FSS) is a 9-item self-report questionnaire designed to measure level of fatigue. The FSS is graded on a 7-point Likert-like scale ranging from 1 ("strongly disagree") to 7 ("strongly agree"). The score for all 9 items is summed to constitute the FSS score. The minimum FSS score is 7 and the maximum score possible is 63. A higher score represents greater fatigue severity. Change was calculated as the value at 6 months minus the value at baseline and reported here. A higher positive score indicates an increase in fatigue symptoms at 6 months compared to baseline, a lower negative score would indicate a decrease in fatigue symptoms over 6 months and a score of 0 would indicate no change in fatigue symptoms over 6 months.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Change in Fatigue Severity Scale (FSS) Score
4.87 score on a scale
Standard Deviation 12.95
2.46 score on a scale
Standard Deviation 15.05
4.80 score on a scale
Standard Deviation 11.97

PRIMARY outcome

Timeframe: Baseline and 6 months

The Beck Depression Inventory Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory that measures depression. There is a four-point scale for each item ranging from 0-3. The total score can range from 0 to 63 points. Higher scores reflect a great level of depression severity.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Change in Beck Depression Inventory Second Edition (BDI-II) Score
2.48 score on a scale
Standard Deviation 5.98
1.92 score on a scale
Standard Deviation 7.39
-0.60 score on a scale
Standard Deviation 4.83

PRIMARY outcome

Timeframe: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, 4 participants (1 Control, 1 AUD, and 2 HCVc) were not included in the analysis because they had missing or corrupted imaging files.

MRI-based diffusion tensor imaging (DTI) tractography is used to measure fractional anisotropy (FA), an indicator of CNS microstructural integrity. Increases in FA may reflect enhanced fiber organization or myelination, while decreases often indicate demyelination, axonal loss, or reduced coherence of white matter tracts. The JHU white-matter tractography atlas was used to extract FA values from 20 structures. Percent change was calculated. A positive number indicates an increase in FA after 6 months and a negative number indicates a decrease in FA from baseline to 6 months.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=14 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=8 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=2 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Anterior thalamic radiation
0.297 percent change
Standard Deviation 2.158
-0.768 percent change
Standard Deviation 1.850
-1.189 percent change
Standard Deviation 1.125
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Cingulum cingulate gyrus
0.341 percent change
Standard Deviation 2.384
-0.231 percent change
Standard Deviation 2.410
-2.038 percent change
Standard Deviation 0.731
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Corticospinal tract
0.337 percent change
Standard Deviation 1.045
-0.522 percent change
Standard Deviation 1.402
-1.271 percent change
Standard Deviation 0.737
Change in Fractional Anisotropy (FA) in White Matter Tracts
Forceps major
0.400 percent change
Standard Deviation 2.038
-0.295 percent change
Standard Deviation 2.426
-2.476 percent change
Standard Deviation 0.821
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Inferior fronto-occipital fasciculus
0.542 percent change
Standard Deviation 2.558
0.005 percent change
Standard Deviation 2.503
-1.700 percent change
Standard Deviation 0.534
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Inferior fronto-occipital fasciculus
0.014 percent change
Standard Deviation 2.693
-0.410 percent change
Standard Deviation 1.772
-1.756 percent change
Standard Deviation 0.072
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Uncinate fasciculus
-0.409 percent change
Standard Deviation 3.708
-1.324 percent change
Standard Deviation 2.321
-1.609 percent change
Standard Deviation 1.299
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Anterior thalamic radiation
0.416 percent change
Standard Deviation 1.791
-0.612 percent change
Standard Deviation 2.045
-1.953 percent change
Standard Deviation 0.888
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Cingulum cingulate gyrus
0.340 percent change
Standard Deviation 1.557
-0.095 percent change
Standard Deviation 2.210
-1.218 percent change
Standard Deviation 0.224
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Cingulum hippocampus
1.168 percent change
Standard Deviation 3.190
0.259 percent change
Standard Deviation 2.576
-2.062 percent change
Standard Deviation 0.461
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Cingulum hippocampus
-0.113 percent change
Standard Deviation 1.969
-0.612 percent change
Standard Deviation 2.508
-2.015 percent change
Standard Deviation 3.444
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Corticospinal tract
0.130 percent change
Standard Deviation 1.320
-0.166 percent change
Standard Deviation 1.641
-2.396 percent change
Standard Deviation 0.712
Change in Fractional Anisotropy (FA) in White Matter Tracts
Forceps minor
0.317 percent change
Standard Deviation 3.400
-0.805 percent change
Standard Deviation 2.628
-0.986 percent change
Standard Deviation 1.692
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Inferior longitudinal fasciculus
0.474 percent change
Standard Deviation 1.764
-0.002 percent change
Standard Deviation 1.995
-1.790 percent change
Standard Deviation 0.358
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Inferior longitudinal fasciculus
0.017 percent change
Standard Deviation 1.971
-0.234 percent change
Standard Deviation 1.834
-2.245 percent change
Standard Deviation 1.131
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Superior longitudinal fasciculus
0.424 percent change
Standard Deviation 1.429
-0.027 percent change
Standard Deviation 1.492
-1.035 percent change
Standard Deviation 0.744
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Superior longitudinal fasciculus
-0.284 percent change
Standard Deviation 1.760
-0.548 percent change
Standard Deviation 1.260
-1.840 percent change
Standard Deviation 0.379
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Superior longitudinal fasciculus, temporal part
0.540 percent change
Standard Deviation 1.543
-0.158 percent change
Standard Deviation 1.484
-1.363 percent change
Standard Deviation 0.398
Change in Fractional Anisotropy (FA) in White Matter Tracts
Right Superior longitudinal fasciculus, temporal part
-0.017 percent change
Standard Deviation 1.474
-0.671 percent change
Standard Deviation 1.173
-1.525 percent change
Standard Deviation 0.144
Change in Fractional Anisotropy (FA) in White Matter Tracts
Left Uncinate fasciculus
0.462 percent change
Standard Deviation 3.711
0.341 percent change
Standard Deviation 3.566
-1.277 percent change
Standard Deviation 0.614

PRIMARY outcome

Timeframe: Baseline and 6 months

Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, 4 participants (1 Control, 1 AUD, and 2 HCVc) were not included in the analysis because they had missing or corrupted imaging files.

MRI-based diffusion tensor imaging (DTI) tractography is used to measure mean diffusivity (MD), which is the average rate of water diffusion in all directions within brain tissue. An increase in MD often indicates microstructural disruption, such as axonal loss, demyelination, or increased extracellular space due to edema or atrophy and decreases in MD can reflect cellular proliferation or restricted diffusion, as seen in certain types of gliosis or inflammatory conditions. The JHU white-matter tractography atlas was used to extract MD values from 20 structures. Percent change was calculated. A positive number indicates an increase in MD after 6 months and a negative number indicates a decrease in MD from baseline to 6 months.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=14 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=8 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=2 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Cingulum hippocampus
-0.797 percent change
Standard Deviation 1.660
0.015 percent change
Standard Deviation 2.180
1.131 percent change
Standard Deviation 4.550
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Inferior fronto-occipital fasciculus
-0.862 percent change
Standard Deviation 1.155
0.276 percent change
Standard Deviation 1.685
0.861 percent change
Standard Deviation 1.655
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Inferior longitudinal fasciculus
-1.006 percent change
Standard Deviation 1.231
0.082 percent change
Standard Deviation 1.670
1.095 percent change
Standard Deviation 0.914
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Anterior thalamic radiation
-0.740 percent change
Standard Deviation 1.039
0.490 percent change
Standard Deviation 1.129
0.159 percent change
Standard Deviation 1.507
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Anterior thalamic radiation
-0.827 percent change
Standard Deviation 0.993
0.358 percent change
Standard Deviation 1.662
0.393 percent change
Standard Deviation 1.856
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Cingulum cingulate gyrus
-0.835 percent change
Standard Deviation 1.458
0.453 percent change
Standard Deviation 1.269
-0.288 percent change
Standard Deviation 1.983
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Cingulum cingulate gyrus
-0.919 percent change
Standard Deviation 1.566
-0.177 percent change
Standard Deviation 2.080
0.521 percent change
Standard Deviation 0.847
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Cingulum hippocampus
-0.932 percent change
Standard Deviation 2.626
0.099 percent change
Standard Deviation 3.176
2.535 percent change
Standard Deviation 1.258
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Corticospinal tract
-0.372 percent change
Standard Deviation 0.985
0.811 percent change
Standard Deviation 1.180
0.522 percent change
Standard Deviation 0.881
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Corticospinal tract
-0.359 percent change
Standard Deviation 0.701
0.029 percent change
Standard Deviation 0.928
1.169 percent change
Standard Deviation 1.674
Change in Mean Diffusivity (MD) in White Matter Tracts
Forceps major
-0.474 percent change
Standard Deviation 1.542
0.756 percent change
Standard Deviation 1.905
1.771 percent change
Standard Deviation 0.407
Change in Mean Diffusivity (MD) in White Matter Tracts
Forceps minor
-0.832 percent change
Standard Deviation 1.471
0.302 percent change
Standard Deviation 2.164
-0.674 percent change
Standard Deviation 1.426
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Inferior fronto-occipital fasciculus
-1.191 percent change
Standard Deviation 1.161
-0.014 percent change
Standard Deviation 1.291
0.240 percent change
Standard Deviation 0.238
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Inferior longitudinal fasciculus
-1.128 percent change
Standard Deviation 1.374
0.325 percent change
Standard Deviation 1.185
1.089 percent change
Standard Deviation 0.099
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Superior longitudinal fasciculus
-0.806 percent change
Standard Deviation 1.237
0.293 percent change
Standard Deviation 1.154
0.249 percent change
Standard Deviation 0.342
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Superior longitudinal fasciculus
-0.615 percent change
Standard Deviation 1.116
0.276 percent change
Standard Deviation 1.532
0.724 percent change
Standard Deviation 1.051
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Superior longitudinal fasciculus, temporal part
-0.892 percent change
Standard Deviation 1.243
0.370 percent change
Standard Deviation 1.109
0.516 percent change
Standard Deviation 0.272
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Superior longitudinal fasciculus, temporal part
-0.777 percent change
Standard Deviation 1.093
0.284 percent change
Standard Deviation 1.340
0.282 percent change
Standard Deviation 0.952
Change in Mean Diffusivity (MD) in White Matter Tracts
Left Uncinate fasciculus
-1.367 percent change
Standard Deviation 1.541
-0.334 percent change
Standard Deviation 1.792
-0.633 percent change
Standard Deviation 0.121
Change in Mean Diffusivity (MD) in White Matter Tracts
Right Uncinate fasciculus
-0.864 percent change
Standard Deviation 1.716
0.582 percent change
Standard Deviation 2.398
0.586 percent change
Standard Deviation 1.752

PRIMARY outcome

Timeframe: Baseline and 6 months

Change was calculated as the value at 6 months minus the value and baseline. A positive number indicates an increase in inflammatory markers in plasma samples and a negative value indicates a decrease in inflammatory markers at 6 months.

Outcome measures

Outcome measures
Measure
Control (AUD-)
n=27 Participants
-Without Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Alcohol Use Disorder (AUD+)
n=14 Participants
-With Alcohol Use Disorder and without HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
HCVc
n=5 Participants
-Adults treated for HCV Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later). Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)
MLR
-0.03 cell count x 10^3/uL [ratio]
Standard Deviation 0.07
0.03 cell count x 10^3/uL [ratio]
Standard Deviation 0.07
0.45 cell count x 10^3/uL [ratio]
Standard Deviation 0.70
Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)
NLR
-0.36 cell count x 10^3/uL [ratio]
Standard Deviation 0.58
0.17 cell count x 10^3/uL [ratio]
Standard Deviation 0.52
-0.50 cell count x 10^3/uL [ratio]
Standard Deviation 0.42

Adverse Events

Control (AUD-)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Alcohol Use Disorder (AUD+)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

HCVc

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Loftis, PhD

VA Portland Health Care System

Phone: 503-220-8262

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place